Relapsing Polychondritis


Relapsing polychondritis (RP) is a rare disorder and the aetiology remains unknown. It is often associated with autoimmune disorders, and the presence of antibodies to type II collagen suggests that it may be immunologically mediated. Between 25% and 35% of patients have other autoimmune diseases too.1

The term 'relapsing polychondritis' (RP) was first used in 19602 to describe a very rare disease which is characterised by recurrent episodes of inflammation of cartilaginous structures and other connective tissues, which may involve many organs. It can involve all types of cartilage including that of joints, tracheo-bronchial tree, ear and nose and connective tissues rich in proteoglycans, such as in the heart, eye, blood vessels and inner ear.3 (Copied from


It is a multisystem disorder and so can present in many ways:

  • Weight loss.
  • External ear pain (present in almost all cases).
  • Dizziness and ataxia of vestibular origin.
  • Hearing impairment (46% in later stages).
  • Arthralgia (50-85%, may affect any synovial joint).
  • Nasal pain and chondritis.
  • Hoarseness and difficulty talking.
  • Glottic, subglottic and laryngeal inflammation and oedema.
  • Cough, dyspnoea, wheezing and choking.
  • Costochondritis (may lead to joint dissolution and flail chest).
  • Recurrent scleritis and episcleritis.
  • Cardiovascular involvement including valve problems, pericarditis, myocarditis, myocardial infarction, aneurysms.
  • Renal involvement, glomerulonephritis, glomerulosclerosis (associated with poorer prognosis - 30% survival at 10 years).
  • Nervous system involvement (rare), cranial nerve lesions, aneurysms.

Copied from


Unknown. Presumably an autoimmune response directed against cartilage.




As it is a rare multisystem disorder with no specific diagnostic test and numerous possible symptoms, a number of diagnostic criteria have been devised. The most widely used are the McAdam's criteria.1 The following features are sought:

  • Recurrent chondritis of both auricles.
  • Chondritis of nasal cartilages.
  • Chondritis of the respiratory tract, involving laryngeal or tracheal cartilage.
  • Non-erosive inflammatory polyarthritis.
  • Inflammation of ocular structures.
  • Cochlear or vestibular damage.

In addition, cartilage biopsy may be taken to confirm a compatible histological picture. Biopsy of cartilage is not to be undertaken lightly. It does not have its own blood supply and it heals poorly, if at all.

There are 3 grounds to make the diagnosis:4

  • At least 3 criteria: no histological confirmation is required.
  • One or more of these features, including histological confirmation.
  • Chondritis in 2 or more separate anatomical locations with response to steroids and/or dapsone.

Alternative criteria have been proposed with 2 possible routes to diagnosis:3

  • Proven inflammation in 2 of 3 of the auricular, nasal, or laryngotracheal cartilages.
  • Proven inflammation in 1 of 3 of the auricular, nasal, or laryngotracheal cartilages plus 2 other signs, including ocular inflammation, vestibular dysfunction, seronegative inflammatory arthritis, and hearing loss.
Differential diagnosis

A number of conditions can resemble relapsing polychondritis (RP) and may even occur in association with it. Wegener's granulomatosis and systemic lupus erythematosus often have to be excluded before a diagnosis of RP is entertained.

Other conditions may mimic the clinical presentation, including trauma, infections, allergic reactions and tumour.


Taken from


PrognosisThe disease follows a relapsing and remitting course with steady progression of the disease. The prognosis for any individual will vary considerably depending on which systems are involved and their response to therapy. With earlier recognition of the disease and optimal treatment, the prognosis has improved, and in one study a 94% survival rate was reported with an average 8-year follow-up.10 Up to 50% of deaths will be due to pneumonia following involvement of cartilage in the respiratory system, with cardiovascular involvement being the next most common cause of death. Another group found that respiratory disease caused only 10% of deaths.3 The most frequent causes of death were infection, systemic vasculitis, and malignancy.


Taken from


Many systems can be involved and it is important to adopt a team approach with good communication between the specialists involved.


Because of involvement of auricular and nasal cartilage, counselling, support and specialist cosmetic advice may be required due to the change in facial appearance.


The rarity of the disorder has meant that few clinical trials have been performed.

  • Corticosteroids remain the most commonly used therapeutic measure but, despite bringing relief from symptoms and reducing the severity and duration of relapses, they do not appear to alter the disease progression.5
  • Other agents have been used such as dapsone, methotrexate, colchicines, cyclophosphamide and azathioprine with apparent success, although the numbers involved are small and no controlled trials have been performed.
  • In recent years, anti-TNF-alpha drugs have been tried and there are a number of case reports in the literature:
    • Infliximab and etanercept are effective in some subtypes of juvenile idiopathic arthritis and have been tried in children with relapsing polychondritis (RP).6 Although frequent, adverse events could be controlled most of the time.
    • Infliximab has been tried for respiratory complications.7
    • It has been tried in RP refractory to other treatments, with apparent success.8


  • Collapse of upper airways may require tracheostomy.
  • Males are more susceptible to heart valve disease, possibly requiring aortic valve replacement.9
Taken from


None that I can think of!